The DOI matches its Crossref record.
New Treatment Approach in Indian Visceral Leishmaniasis: Single‐Dose Liposomal Amphotericin B Followed by Short‐Course Oral Miltefosine
Open accessAbstract
BACKGROUND: In Bihar, India, home to nearly one-half of the world's burden of visceral leishmaniasis, drug resistance has ended the usefulness of pentavalent antimony, which is the traditional first-line treatment. Although monotherapy with other agents is available, the use of 2 drugs with different modes of action might increase efficacy, shorten treatment duration, enhance compliance, and/or reduce the risk of parasite resistance. To test the feasibility of a new approach to combination therapy in visceral leishmaniasis (also known a kala-azar), we treated Indian patients with a single infusion of liposomal amphotericin B (L-AmB), followed 1 day later by short-course oral miltefosine. METHODS: We used a randomized, noncomparative, group-sequential, triangular design and assigned 181 subjects to treatment with 5 mg/kg of L-AmB alone (group A; 45 subjects), 5 mg/kg of L-AmB followed by miltefosine for 10 days (group B; 46 subjects) or 14 days (group C; 45 subjects), or 3.75 mg/kg of L-AmB followed by miltefosine for 14 days (group D; 45 subjects). When it became apparent that all regimens were effective, 45 additional, nonrandomized patients were assigned to receive 5 mg/kg of L-AmB followed by miltefosine for 7 days (group E). RESULTS: Each regimen was satisfactorily tolerated, and all 226 subjects showed initial apparent cure responses. Nine months after treatment, final cure rates were similar: group A, 91% (95% confidence interval [CI], 78%-97%]; group B, 98% (95% CI, 87%-100%); group C, 96% (95% CI, 84%-99%]; group D, 96% (95% CI, 84%-99%); and group E, 98% (95% CI, 87%-100%). CONCLUSIONS: These results suggest that treatment with single-dose L-AmB followed by 7-14 days of miltefosine is active against Indian kala-azar. This short-course, sequential regimen warrants additional testing in India and in those regions of endemicity where visceral leishmaniasis may be more difficult to treat. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00370825 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
Dorlo, T. P. C., Balasegaram, M., Beijnen, J. H., & de Vries, P. J. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks275 · Cited by 775
Aronson, N., Herwaldt, B. L., Libman, M., Pearson, R., Lopez-Velez, R., Weina, P., Carvalho, E. M., Ephros, M., Jeronimo, S., & Magill, A. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw670 · Cited by 458
Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Sundar, S., Chakravarty, J., Agarwal, D., Rai, M., & Murray, H. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0903627 · Cited by 434
Self-citationLeishmaniasis chemotherapy—challenges and opportunities
Croft, S. L., & Olliaro, P. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03630.x · Cited by 424
Self-citationUse of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions
Haldar, A. K., Sen, P., & Roy, S. (2011) · Molecular Biology International · doi:10.4061/2011/571242 · Cited by 408
Sundar, S., Sinha, P. K., Rai, M., Verma, D. K., Nawin, K., Alam, S., Chakravarty, J., Vaillant, M., Verma, N., Pandey, K., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62050-8 · Cited by 337
Self-citationCombination therapy for visceral leishmaniasis
van Griensven, J., Balasegaram, M., Meheus, F., Alvar, J., Lynen, L., & Boelaert, M. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70011-6 · Cited by 336
An update on pharmacotherapy for leishmaniasis
Sundar, S., & Chakravarty, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.973850 · Cited by 320
Self-citationDrug resistance in leishmaniasis
Chakravarty, J., & Sundar, S. (2010) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.62887 · Cited by 270
Self-citationLeishmaniasis: an update of current pharmacotherapy
Sundar, S., & Chakravarty, J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.755515 · Cited by 261
Self-citationChemotherapy of leishmaniasis: present challenges
ULIANA, S. R. B., TRINCONI, C. T., & COELHO, A. C. (2018) · Parasitology · doi:10.1017/s0031182016002523 · Cited by 261
Recent advances and new strategies on leishmaniasis treatment
Roatt, B. M., de Oliveira Cardoso, J. M., De Brito, R. C. F., Coura-Vital, W., de Oliveira Aguiar-Soares, R. D., & Reis, A. B. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10856-w · Cited by 253
Liposomal amphotericin B and leishmaniasis: Dose and response
Sundar, S., & Chakravarty, J. (2010) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.62886 · Cited by 217
Self-citation
Metadata
- Authors
- Sundar, S., Rai, M., Chakravarty, J., Agarwal, D., Agrawal, N., Vaillant, M., Olliaro, P., & Murray, H. W.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-10-15
- Volume
- 47
- Issue
- 8
- Pages
- 1000-1006
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2152820036
- Cited by
- 209
- References
- 0
- FWCI
- 17.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.